Clostridioides difficile Infection: Clinical Practice and Health Outcomes in 6 Large Tertiary Hospitals in Eastern Australia
- Author(s)
- Stewart, AG; Chen, SCA; Hamilton, K; Harris-Brown, T; Korman, TM; Figtree, M; Worth, LJ; Kok, J; Van der Poorten, D; Byth, K; Slavin, MA; Paterson, DL;
- Details
- Publication Year 2023-06,Volume 10,Issue #6,Page ofad232
- Journal Title
- Open Forum Infectious Diseases
- Publication Type
- Research article
- Abstract
- BACKGROUND: Clostridioides difficile infection (CDI) is associated with significant morbidity and mortality in both healthcare and community settings. We aimed to define the predisposing factors, risks for severe disease, and mortality determinants of CDI in eastern Australia over a 1-year period. METHODS: This is an observational retrospective study of CDI in hospitalized patients aged >/=18 years in 6 tertiary institutions from 1 January 2016 to 31 December 2016. Patients were identified through laboratory databases and medical records of participating institutions. Clinical, imaging, and laboratory data were input into an electronic database hosted at a central site. RESULTS: A total of 578 patients (578 CDI episodes) were included. Median age was 65 (range, 18-99) years and 48.2% were male. Hospital-onset CDI occurred in 64.0%. Recent antimicrobial use (41.9%) and proton pump inhibitor use (35.8%) were common. Significant risk factors for severe CDI were age <65 years (P < .001), malignancy within the last 5 years (P < .001), and surgery within the previous 30 days (P < .001). Significant risk factors for first recurrence included severe CDI (P = .03) and inflammatory bowel disease (P = .04). Metronidazole was the most common regimen for first episodes of CDI with 65.2% being concordant with Australian treatment guidelines overall. Determinants for death at 60 days included age >/=65 years (P = .01), severe CDI (P < .001), and antibiotic use within the prior 30 days (P = .02). Of those who received metronidazole as first-line therapy, 10.1% died in the 60-day follow-up period, compared to 9.8% of those who received vancomycin (P = .86). CONCLUSIONS: Patients who experience CDI are vulnerable and require early diagnosis, clinical surveillance, and effective therapy to prevent complications and improve outcomes.
- Publisher
- Oxford University Press
- Keywords
- Australia; Cdi; Clostridioides difficile; hospital epidemiology
- Department(s)
- Infectious Diseases
- PubMed ID
- 37274181
- Publisher's Version
- https://doi.org/10.1093/ofid/ofad232
- Open Access at Publisher's Site
https://doi.org/10.1093/ofid/ofad232- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-05 06:33:30
Last Modified: 2023-09-05 06:34:32